Experimental demonstration of energy-chirp control in relativistic electron bunches using a corrugated pipe.

The first experimental study is presented of a corrugated wall device that uses wakefields to remove a linear energy correlation in a relativistic electron beam (a "dechirper"). Time-resolved measurements of both longitudinal and transverse wakefields of the device are presented and compared with simulations. This study demonstrates the feasibility to employ a dechirper for precise control of the beam phase space in the next generation of free-electron-lasers.

Therapeutic effects of combination using glucosamine plus tacrolimus (FK-506) on the development of atopic dermatitis-like skin lesions in NC/Nga mice.

Tacrolimus (FK-506) has been found to exhibit potent inhibitory effects on spontaneously developed dermatitis. We previously showed that glucosamine prevents the development of Atopic dermatitis (AD)-like skin lesions in NC/Nga mice. The aims of our study were to investigate the synergistic therapeutic efficacy of combination of glucosamine plus FK-506 in dermatophagoides farina (Df)-induced AD-like skin lesions in NC/Nga mice and to determine the underlying therapeutic mechanisms. The Df-induced NC/Nga mice with a clinical score of 8 were used for treatment with glucosamine (500 mg/kg) alone, FK-506 (1.0 mg/kg) or in combination. The synergistic effects of combination therapy were evaluated by dermatitis scores, skin histology and immunological parameters such as IgE, Th2-mediated cytokines and chemokines, CD3(+) T cells and CLA(+) T cells. Combined therapy using glucosamine plus FK-506 improved the development of AD-like skin lesions as exemplified by a significant decrease in total skin symptom severity scores. The suppression of dermatitis by combined therapy was accompanied by a decrease in the plasma level of IgE and in the splenic level of IL-5, IL-13, TARC and eotaxin. Histological finding indicated that the dermal infiltration of inflammatory cells including mast cells and eosinophils was greatly reduced. Particularly, immunohistological evaluation reveals a reduction in CD3(+) T cells and CLA(+) cells in the combined therapy. Our findings suggest that combination therapy of glucosamine plus FK-506 was more synergistic efficacy than single-modality treatment with either alone to improve the development of established dermatitis in NC/Nga mice model. This combined immunosuppressive therapy may provide an effective therapeutic strategy for the treatment of AD.

Glucosamine improved atopic dermatitis-like skin lesions in NC/Nga mice by inhibition of Th2 cell development.

Dysregulated Th subset responses, characterized by Th2-dominant allergic inflammation, are thought to be central to the pathogenesis of atopic dermatitis (AD). Glucosamine has been shown to have immunosuppressive properties, but its effect on AD has not been examined. In this study, the immunoregulatory effects of glucosamine, using dermatophagoides farinae (Df)-induced AD-like skin lesions in NC/Nga mice, were investigated. The clinical scores were reduced significantly by the treatment with glucosamine at 10 and 20 mg/day. Histological analysis of the skin also revealed that treatment of glucosamine at 10 and 20 mg/day significantly reduced the inflammatory cellular infiltrate, including mast cells and eosinophils. The levels of serum IgE and Th2 cytokines in spleen cells were reduced, whereas no significant change was detected in IFN-γ, a Th1 cytokine. To determine the mechanism associated with inhibition of the Th2 immune response, the effects of glucosamine on the selective differentiation pathway of the Th subset in vitro was examined in NC/Nga mice. The results showed that glucosamine suppressed the differentiation of naïve CD4(+) T cells to Th2 cells in vitro. On the basis of in vivo and in vitro results of the NC/Nga mice, the immunobiological effects of glucosamine on peripheral blood mononuclear cells from patients with AD were examined. The production of Th2 cytokines, such as IL-4 and IL-5, was significantly decreased after in vitro administration of glucosamine, which suggest that glucosamine might be a useful immunomodulatory agent for the treatment of human AD.

The effect of esmolol-induced controlled hypotension in combination with acute normovolemic hemodilution on cerebral oxygenation.

BACKGROUND: It is possible to perform acute normovolemic hemodilution (ANH) in combination with controlled hypotension (CH). In this randomized prospective study, we examined the effect of the combination of ANH and CH on cerebral oxygenation using near-infrared spectroscopy. METHODS: Fifty-six patients undergoing major orthopedic surgery were randomly assigned to either group A (ANH only) or group CH (CH in combination with ANH). In group CH, CH was induced with esmolol. The regional cerebral oxygen saturation (rSO(2)) was monitored continuously and was compared between the two groups before and after ANH, 30 min (OP(30)) and 90 min (OP(90)) after the beginning of surgery and after the completion of surgery. RESULTS: The value of rSO(2) was the same in both groups in the absence of CH (at baseline: group A, 70.1 +/- 6.0%; group CH, 69.9 +/- 6.7%; after surgery: group A, 64.5 +/- 4.9%; group CH, 64.3 +/- 5.8%). However, in the presence of CH, rSO(2) values were significantly lower in group CH than in group A (at OP(30): group A: 60.4 +/- 3.4%; group CH, 55.9 +/- 7.3%; P < 0.01; at OP(90): group A, 58.3 +/- 5.2%; group CH, 53.5 +/- 6.5%; P < 0.001). The number of patients with rSO(2) < 50% was significantly higher in group CH (14.3%) than in group A (3.8%). CONCLUSION: ANH in combination with esmolol-induced CH causes a significant decrease in cerebral oxygen saturation compared with ANH alone.

Depth of a central venous catheter tip: length of insertion guideline for pediatric patients.

BACKGROUND: In pediatric patients, several studies have been undertaken to establish central venous catheter (CVC) tip optimal depth. Assessments of catheter tip position using chest radiographs may be misleading, whereas transesophageal echocardiography (TEE) has been shown to accurately monitor catheter tip placement at the superior vena cava-right atrial (SVC-RA) junction. The aim of this study was to issue a guideline for ideal catheter insertion depth, from the right internal jugular vein (IJV) using TEE to confirm the position of the catheter tip at the SVC-RA junction. METHODS: Over a 6-month period, we studied 60 right internal jugular vein catheterizations in infants and children undergoing surgery for congenital heart disease. Positions of CVC tips were confirmed to be at the SVC-RA junction by TEE. Distance from the skin puncture site to the SVC-RA junction, height, weight, and age were recorded. RESULTS: Distances measured were found to be highly correlated with patient height. The following guideline allows the CVC tip to be positioned above the RA in 97.5% of patients with an accuracy of 95%: optimal depth of insertion (cm) = 1.7 + (0.07 x height) in patients whose height is between 40 and 140 cm. CONCLUSION: The model proposed for the insertion of the CVC tip in pediatric patients could be used to prevent inadvertent catheter tip placement into the atrium.

Human B cell interleukin 10.

Interleukin 10 (IL-10) is a novel lymphokine which exhibits strong DNA and amino acid sequence homology to BCRF1, an open reading frame in the Epstein-Barr virus genome. Using a wide panel of EBV positive and EBV negative cell lines, it has been shown that EBV positive B cell lines derived from patients with AIDS and Burkitt's lymphoma (AABCL) secrete large quantities of B cell IL-10, compared with EBV-positive B cell lines obtained from patients with undifferentiated lymphomas of Burkitt's and non-Burkitt's types. In contrast, EBV-negative B cell lines do not express IL-10 by Northern blot analysis, ELISA or even PCR. B cell IL-10 is confined to a narrow window in the B cell differentiation pathway, and whereas IL-10 expression is detected in mature and preplasmacytic stages, none of the pro-B, pre-B, or myeloma cell lines produce IL-10. EBV exerts direct effect on the production of B cell IL-10, and purified tonsillar B cells infected with EBV were triggered to secrete IL-10. The large amount of IL-10 secreted by B cells derived from AIDS-related lymphomas suggests that HIV-1 also exerts direct effect on IL-10 secretion. B cell IL-10 may function as autocrine growth factor for B cell lymphomas, and both IL-10 and BCRF1 seem to be involved in the pathophysiology of non-Hodgkin's lymphomas.

End of life care for infants with AIDS: ethical and legal issues.

Complex cases involving end-of-life care for infants with AIDS raise a variety of ethical and legal concerns. Health care providers should understand the issues involving proper treatment, including adequate relief of pain at the end of life, and a context for examining the suffering of caregivers.

Comparison of a daily and three intermittent retreatment regimens for pulmonary tuberculosis administered under programme conditions.

One daily and 3 thrice weekly retreatment regimens given for 12 months under programme conditions were compared. The daily regimen was rifampicin and ethambutol (RE7). The three intermittent regimens also contained rifampicin and ethambutol: one of them, rifampicin and ethambutol throughout (RE3); the next one supplemented with pyrazinamide for the first 3 months (REZ3); the last one supplemented with prothionamide for the first 3 months (REPt3). The pyrazinamide containing regimen was subdivided into ordinary and high dose groups. The subjects for retreatment were those who have had, at least, more than 6 months of initial triple chemotherapy of isoniazid, PAS and streptomycin at the health centres, and failed to convert to bacteriologically negative status. Among 419 patients who were available for sensitivity tests before commencing retreatment, 393 (94.3%) were resistant to isoniazid. Six hundred and seventy-four patients (674) were allocated randomly to the regimens: 64 patients were excluded due to various pretreatment reasons and 109 did not complete 12 months of chemotherapy. There remain 501 patients who completed their retreatment. As assessed at 12 months, a bacteriologically favourable response was achieved in 68% of 135 RE7 patients, 62% of 129 RE3 patients, 74% of 132 REZ3 patients, and in 79% of 108 REPt3 patients. Adverse reactions were uncommon: 4% in RE7, 5% in RE3 and 9% in REZ3, but 32% in REPt3. Relapse rates during 2 years after termination of chemotherapy were 15% in RE7, 14% in RE3 and REZ3, and 26% in REPt3, as calculated by life table analysis.

Pancreaticogastrostomy: a further evaluation.

The anastomosis between the remaining pancreas and the intestinal tract after various types of pancreatic resection has been the site of complications responsible for considerable morbidity and mortality. After Whipple resections reestablishment of pancreatic-intestinal continuity has generally been accomplished in some manner between the pancreas and upper jejunum. This suture line has at times failed, often as the result of postoperative pancreatitis, giving rise to hemorrhage, abscess, and fistula formation. Since 1963, 25 patients undergoing pancreaticoduodenal resection have had some portion of their pancreas implanted into the back wall of the stomach. The operations have been done by the resident and senior staff of the Department of Surgery at the University of Pennsylvania. Morbidity has decreased and operative mortality has fallen from 20-30% to 8%. The technique is not difficult and there seems to be less tendency for the anastomosis to leak. Pancreatic function is usually adequate. The procedure is useful after radical resection of the pancreaticoduodenal region or at times after pancreatic trauma.